How much revenue does Alembic Pharmaceuticals make?

Alembic Pharmaceuticals reported 65.40 billion INR in revenue for fiscal year 2025, up 7.0% from 61.12 billion INR in fiscal year 2024. In Q1 2026 revenue was 17.11 billion INR.

Where does Alembic Pharmaceuticals make most of its revenue?

Outside India: 61% of revenue by region in fiscal year 2025, followed by India (39%).

What companies are similar to Alembic Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Caplin Point Laboratories Limited (CAPLIPOINT.NS), Pfizer Limited (PFIZER.NS), Eris Lifesciences Limited (ERIS.NS), Jubilant Pharmova Limited (JUBLPHARMA.NS).

Alembic Pharmaceuticals Limited (APLLTD.BO) Stock

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health...

At a glance

Alembic Pharmaceuticals reported revenue of 65.40 billion INR for fiscal year 2025, up 7.0% from fiscal year 2024, and net income of 5.83 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 17.11 billion INR, up 9.5% from a year before. Outside India was its largest region in fiscal year 2025, with 61% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.